Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 6 (2009), Issue 11 (November)

1. Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis: an alternative in patients with contraindications to thrombolysis.
   J Vasc Surg, 50(5): 1092-8. [Abstract] [Full-text]
2. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
   Lancet, 374(9700): 1512-20. [Abstract] [Full-text]
3. Patients' expectations before and satisfaction after ultrasound guided foam sclerotherapy for varicose veins.
   Eur J Vasc Endovasc Surg, 38(5): 642-7. [Abstract] [Full-text]
4. Reversible neurological deficit after foam sclerotherapy.
   Eur J Vasc Endovasc Surg, 38(5): 648-9. [Abstract] [Full-text]
5. Infections related to intrathecal baclofen therapy in children and adults: frequency and risk factors.
   J Neurosurg Pediatr, 4(5): 487-93. [Abstract] [Full-text]
6. Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.
   Am J Epidemiol, 170(10): 1241-9. [Abstract] [Full-text]
7. Lesion patterns in successful and failed thrombolysis in middle cerebral artery stroke.
   Neuroradiology, 51(12): 865-71. [Abstract] [Full-text]
8. Self-assembled hyaluronic acid nanoparticles for active tumor targeting.
   Biomaterials, 31(1): 106-14. [Abstract] [Full-text]
9. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
   Jpn J Clin Oncol, 39(11): 713-9. [Abstract] [Full-text]
10. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial.
    Ophthalmology, 116(11): 2149-57.e1. [Abstract] [Full-text]
11. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
    Jpn J Clin Oncol, 39(11): 707-12. [Abstract] [Full-text]
12. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma.
    Jpn J Clin Oncol, 39(11): 720-6. [Abstract] [Full-text]
13. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.
    Ann Intern Med, 151(9): 650-61. [Abstract] [Full-text]
14. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians.
    Ann Intern Med, 151(9): 639-49. [Abstract] [Full-text]
15. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol, 115(3): 396-400. [Abstract] [Full-text]
16. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.
    Gynecol Oncol, 115(3): 438-42. [Abstract] [Full-text]
17. The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients.
    Gynecol Oncol, 115(3): 343-8. [Abstract] [Full-text]
18. Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
    Gynecol Oncol, 115(3): 389-95. [Abstract] [Full-text]
19. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Gynecol Oncol, 115(3): 377-81. [Abstract] [Full-text]
20. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.
    Gynecol Oncol, 115(3): 382-8. [Abstract] [Full-text]
21. Novel cholesterol-based cationic lipids for gene delivery.
    J Med Chem, 52(21): 6558-68. [Abstract] [Full-text]
22. High celecoxib-loaded nanoparticles prepared by a vibrating nozzle device.
    J Microencapsul, 26(8): 748-59. [Abstract] [Full-text]
23. Formation of size-controlled nano carrier systems by self-assembly.
    J Microencapsul, 26(8): 722-33. [Abstract] [Full-text]
24. Respiratory delivery of theophylline by size-targeted starch microspheres for treatment of asthma.
    J Microencapsul, 26(8): 701-10. [Abstract] [Full-text]
25. Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres.
    J Microencapsul, 26(8): 692-700. [Abstract] [Full-text]
26. Essential oil from Zanthoxylum tingoassuiba loaded into multilamellar liposomes useful as antimicrobial agents.
    J Microencapsul, 26(8): 684-91. [Abstract] [Full-text]
27. Preparation and evaluation of microspheres prepared from novel polyester-ibuprofen conjugates blended with non-conjugated ibuprofen.
    J Microencapsul, 26(8): 676-83. [Abstract] [Full-text]
28. Can rhBMP-2 containing collagen sponges enhance bone repair in ovariectomized rats?: a preliminary study.
    Clin Orthop Relat Res, 467(12): 3113-20. [Abstract] [Full-text]
29. Successful spinal fusion by E. coli-derived BMP-2-adsorbed porous beta-TCP granules: a pilot study.
    Clin Orthop Relat Res, 467(12): 3206-12. [Abstract] [Full-text]
30. Starch-poly-epsilon-caprolactone microparticles reduce the needed amount of BMP-2.
    Clin Orthop Relat Res, 467(12): 3138-48. [Abstract] [Full-text]
31. Synthetic alginate is a carrier of OP-1 for bone induction.
    Clin Orthop Relat Res, 467(12): 3149-55. [Abstract] [Full-text]
32. Experimental study of the preparation of targeted microbubble contrast agents carrying urokinase and RGDS.
    Ultrasonics, 49(8): 676-81. [Abstract] [Full-text]
33. Ultrasound triggered cell death in vitro with doxorubicin loaded poly lactic-acid contrast agents.
    Ultrasonics, 49(8): 628-33. [Abstract] [Full-text]
34. Peripheral intravenous power injection of iodinated contrast media: the impact of temperature on maximum injection pressures at different cannula sizes.
    Acad Radiol, 16(12): 1502-8. [Abstract] [Full-text]
35. Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia.
    J Acquir Immune Defic Syndr, 52(4): 443-51. [Abstract] [Full-text]
36. Changes in postmenopausal hormone replacement therapy use among women with high cardiovascular risk.
    Am J Public Health, 99(12): 2184-7. [Abstract] [Full-text]
37. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
    Br J Cancer, 101(10): 1658-63. [Abstract] [Full-text]
38. Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals?
    Soc Sci Med, 69(11): 1643-50. [Abstract] [Full-text]
39. Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes.
    Soc Sci Med, 69(11): 1681-90. [Abstract] [Full-text]
40. Outcome reporting in industry-sponsored trials of gabapentin for off-label use.
    N Engl J Med, 361(20): 1963-71. [Abstract] [Full-text]
41. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Scand J Immunol, 70(6): 608-13. [Abstract] [Full-text]
42. Live FISH: imaging mRNA in living neurons.
    J Neurosci Res, 88(1): 55-63. [Abstract] [Full-text]
43. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
    Eur J Surg Oncol, 35(12): 1306-11. [Abstract] [Full-text]
44. Implementation of clinical practice guidelines in dental settings.
    J Evid Based Dent Pract, 9(4): 183-93. [Abstract] [Full-text]
45. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model.
    Biomaterials, 31(3): 541-51. [Abstract] [Full-text]
46. Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling.
    Toxicology, 265(3): 87-95. [Abstract] [Full-text]
47. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
    Pediatr Blood Cancer, 54(1): 55-61. [Abstract] [Full-text]
48. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol.
    Pediatr Blood Cancer, 54(1): 71-8. [Abstract] [Full-text]
49. Treatment results of the Ewing sarcoma of bone and prognostic factors.
    Pediatr Blood Cancer, 54(1): 19-24. [Abstract] [Full-text]
50. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
    Int J Cancer, 126(1): 162-70. [Abstract] [Full-text]
51. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004.
    Int J Cancer, 126(1): 208-16. [Abstract] [Full-text]
52. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease.
    J Am Acad Dermatol, 61(6): 1033-43. [Abstract] [Full-text]
53. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier.
    Proc Natl Acad Sci U S A, 106(46): 19268-73. [Abstract] [Full-text]
54. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
    Proc Natl Acad Sci U S A, 106(46): 19503-8. [Abstract] [Full-text]
55. Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer.
    J Surg Oncol, 100(7): 525-8. [Abstract] [Full-text]
56. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?
    J Immunol, 183(11): 6883-92. [Abstract] [Full-text]
57. Intranasal immunization promotes th17 immune responses.
    J Immunol, 183(11): 6933-8. [Abstract] [Full-text]
58. Epigenetics and cancer treatment.
    Eur J Pharmacol, 625(1): 131-42. [Abstract] [Full-text]
59. Nuclear drug delivery to target tumour cells.
    Eur J Pharmacol, 625(1): 174-80. [Abstract] [Full-text]
60. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues.
    Eur J Pharmacol, 625(1): 6-22. [Abstract] [Full-text]
61. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies.
    Eur J Pharmacol, 625(1): 220-33. [Abstract] [Full-text]
62. The effect of genetic variability on drug response in conventional breast cancer treatment.
    Eur J Pharmacol, 625(1): 122-30. [Abstract] [Full-text]
63. The use of coiled-coil proteins in drug delivery systems.
    Eur J Pharmacol, 625(1): 101-7. [Abstract] [Full-text]
64. Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer.
    Eur J Pharmacol, 625(1): 206-19. [Abstract] [Full-text]
65. New, exciting developments in experimental therapies in the early 21st century.
    Eur J Pharmacol, 625(1): 1-5. [Abstract] [Full-text]
66. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
    Biomaterials, 31(4): 757-68. [Abstract] [Full-text]
67. Squalene: A natural triterpene for use in disease management and therapy.
    Adv Drug Deliv Rev, 61(15): 1412-26. [Abstract] [Full-text]
68. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic.
    Adv Drug Deliv Rev, 61(15): 1427-49. [Abstract] [Full-text]
69. Molecular and magnetic resonance imaging: The value of immunoliposomes.
    Adv Drug Deliv Rev, 61(15): 1402-11. [Abstract] [Full-text]
70. Micro- and nanotechnologies for intelligent and responsive biomaterial-based medical systems.
    Adv Drug Deliv Rev, 61(15): 1391-401. [Abstract] [Full-text]
71. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study.
    Neurology, 73(21): 1729-37. [Abstract] [Full-text]
72. Impact of a pharmacist-facilitated hospital discharge program: a quasi-experimental study.
    Arch Intern Med, 169(21): 2003-10. [Abstract] [Full-text]
73. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy.
    Int J Radiat Oncol Biol Phys, 75(5): 1420-9. [Abstract] [Full-text]
74. Estrogen replacement restores flow-induced vasodilation in coronary arterioles of aged and ovariectomized rats.
    Am J Physiol Regul Integr Comp Physiol, 297(6): R1713-23. [Abstract] [Full-text]
75. Use of anterior segment optical coherence tomography to study corneal changes after collagen cross-linking.
    Am J Ophthalmol, 148(6): 844-51.e2. [Abstract] [Full-text]
76. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
    Int J Radiat Oncol Biol Phys, 75(5): 1430-6. [Abstract] [Full-text]
77. Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
    Int J Radiat Oncol Biol Phys, 75(5): 1450-5. [Abstract] [Full-text]
78. Serious complications associated with external intrathecal catheters used in cancer pain patients: a systematic review and meta-analysis.
    Anesthesiology, 111(6): 1346-55. [Abstract] [Full-text]
79. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.
    Br J Cancer, 101(11): 1853-9. [Abstract] [Full-text]
80. Insect GDNF:TTC fusion protein improves delivery of GDNF to mouse CNS.
    Biochem Biophys Res Commun, 390(3): 947-51. [Abstract] [Full-text]
81. An efficient gene-disruption method in Cryptococcus neoformans by double-joint PCR with NAT-split markers.
    Biochem Biophys Res Commun, 390(3): 983-8. [Abstract] [Full-text]
82. Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells.
    Lab Invest, 89(12): 1355-63. [Abstract] [Full-text]
83. Awakening guardian angels: drugging the p53 pathway.
    Nat Rev Cancer, 9(12): 862-73. [Abstract] [Full-text]
84. Fluid management for laparoscopic colectomy: a prospective, randomized assessment of goal-directed administration of balanced salt solution or hetastarch coupled with an enhanced recovery program.
    Dis Colon Rectum, 52(12): 1935-40. [Abstract] [Full-text]
85. Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients.
    AJR Am J Roentgenol, 193(6): 1665-71. [Abstract] [Full-text]
86. Percutaneous aspiration and ethanolamine oleate sclerotherapy for sustained resolution of symptomatic polycystic liver disease: an initial experience.
    AJR Am J Roentgenol, 193(6): 1540-5. [Abstract] [Full-text]
87. The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics.
    Nat Rev Cancer, 9(12): 849-61. [Abstract] [Full-text]
88. A citywide prehospital protocol increases access to stroke thrombolysis in Toronto.
    Stroke, 40(12): 3841-4. [Abstract] [Full-text]
89. Intravenous thrombolysis in stroke attributable to cervical artery dissection.
    Stroke, 40(12): 3772-6. [Abstract] [Full-text]
90. A putrescine-anthracene conjugate: a paradigm for selective drug delivery.
    Biochem J, 424(3): 431-8. [Abstract] [Full-text]
91. Hospital arrival time and intravenous t-PA use in US Academic Medical Centers, 2001-2004.
    Stroke, 40(12): 3845-50. [Abstract] [Full-text]
92. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
    Cancer, 115(23): 5490-8. [Abstract] [Full-text]
93. Human DEAD-box protein 3 has multiple functions in gene regulation and cell cycle control and is a prime target for viral manipulation.
    Biochem Pharmacol, 79(3): 297-306. [Abstract] [Full-text]
94. Optical imaging-guided cancer therapy with fluorescent nanoparticles.
    J R Soc Interface, 7(42): 3-18. [Abstract] [Full-text]
95. Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.
    Cancer Treat Rev, 35(8): 676-84. [Abstract] [Full-text]
96. Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
    Cancer Treat Rev, 35(8): 668-75. [Abstract] [Full-text]
97. Taking a unified approach to teaching and implementing quality improvements across multiple residency programs: the Atlantic Health experience.
    Acad Med, 84(12): 1788-95. [Abstract] [Full-text]
98. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    J Clin Oncol, 27(34): 5685-92. [Abstract] [Full-text]
99. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    J Clin Oncol, 27(34): 5720-6. [Abstract] [Full-text]
100. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
     J Clin Oncol, 27(34): 5713-9. [Abstract] [Full-text]
101. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
     J Clin Oncol, 27(34): 5727-33. [Abstract] [Full-text]
102. Capacity of photodynamic therapy for microbial reduction in periodontal pockets.
     Lasers Med Sci, 25(1): 87-91. [Abstract] [Full-text]
103. Results of surgical treatment compared with ultrasound-guided foam sclerotherapy in patients with varicose veins: a prospective randomised study.
     Eur J Vasc Endovasc Surg, 38(6): 758-63. [Abstract] [Full-text]
104. Ultrasound-guided foam sclerotherapy for the treatment of chronic venous ulceration: a preliminary study.
     Eur J Vasc Endovasc Surg, 38(6): 764-9. [Abstract] [Full-text]
105. Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.
     Jpn J Clin Oncol, 39(12): 791-6. [Abstract] [Full-text]
106. Phase II trial of weekly gemcitabine and split-dose cisplatin for advanced non-small-cell lung cancer.
     Jpn J Clin Oncol, 39(12): 779-83. [Abstract] [Full-text]
107. Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study).
     Jpn J Clin Oncol, 39(12): 847-9. [Abstract] [Full-text]
108. Intra-arterial infusion of chemotherapy in the treatment of penile cancer.
     Jpn J Clin Oncol, 39(12): 825-8. [Abstract] [Full-text]
109. Estrogen replacement in female lung cancer during gefitinib therapy.
     Jpn J Clin Oncol, 39(12): 829-32. [Abstract] [Full-text]
110. Immunotherapy combined with chemotherapy in the treatment of tumors.
     Neurosurg Clin N Am, 21(1): 187-94. [Abstract] [Full-text]
111. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy.
     Neurosurg Clin N Am, 21(1): 181-6. [Abstract] [Full-text]
112. The 26 S proteasome: from basic mechanisms to drug targeting.
     J Biol Chem, 284(49): 33713-8. [Abstract] [Full-text]
113. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells.
     Prostate, 70(1): 27-36. [Abstract] [Full-text]
114. Regional antibiotic delivery for the treatment of experimental prosthetic graft infections.
     J Surg Res, 157(2): 223-6. [Abstract] [Full-text]
115. Self-microemulsifying and microemulsion systems for transdermal delivery of indomethacin: effect of phase transition.
     Colloids Surf B Biointerfaces, 75(2): 595-600. [Abstract] [Full-text]
116. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC).
     Colloids Surf B Biointerfaces, 75(2): 538-42. [Abstract] [Full-text]
117. Preparation of chitosan microspheres by ionotropic gelation under a high voltage electrostatic field for protein delivery.
     Colloids Surf B Biointerfaces, 75(2): 448-53. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.